Abstracts logical dimension. Correlation coefficients in patients clinically stable between D0 and D28; were all greater than 0.84 for all dimensions of ULL-27. The sensitivity analysis between D0 and D28 in patients with active disease demonstrated significant differences between mean scores for all ULL-27 dimensions. CONCLUSION: Volume of oedema poorly reflects the impact of the illness upon the patient. The ULL-27 scale seems to be a consistent instrument. 
COMPARISON BETWEEN INVESTIGATOR AND PATIENT'S GLOBAL HEALTH ASSESSMENTS USING CALCULATED HUI-III AND SF-36 UTILITY VALUES

OBJECTIVE:
To compare patients' own global health assessment item of the SF-36 (SF-1) and investigators' global health assessment (GLBHLT) with values calculated for Health Utilities Index (HUI-III) and SF-36 preferencebased (SF-6D), in patients with coronary artery disease (CAD). SF-1 is considered a coarse measure for patients' own health assessment while GLBHLT is a widely used clinical-trials endpoint. METHODS: Baseline data of the SF-36, HUI-III and GLBHLT were collected for 331 patients enrolled in a double-blind, multinational, phase III clinical trial. Both the SF-1 and GLBHLT rate patients' health on a scale of one to five, where one is excellent and five is poor. RESULTS: Correlation coefficients (r) between the SF-1 and HUI-III, and the SF-1 and SF-6D were 0.501, 0.508, respectively (p ϭ .001). An r ϭ 0.27 between the SF-1 and GLBHLT was found significant, albeit the magnitude was almost half of those calculated for the SF-1 and SF-6D or the SF-1 and HUI-III. Calculated SF-6D and HUI-III values for GLBHLT ϭ 1 (excellent) were 0.74 and 0.74 compared with the corresponding SF-1 values of 0.81 and 0.83, respectively. Also the SF-6D and HUI-III values for GLBHLT ϭ 5 (poor) were 0.59 and 0.43 compared with the corresponding SF-1 values of 0.54 and 0.21, respectively. CONCLUSION: The SF-1 as a rough estimate of the patient's own health, yielded a stronger correlation with utilities calculated for HUI-III and SF-6D while GL-BHLT, considered a routine measure in clinical trials, yielded much weaker correlation. Confirmation of these findings is needed to assess if GLBHLT is a fair representation of the health of patients with CAD. Roche Belgium, Brussels, Belgium OBJECTIVES: Obesity is a very common condition in type 2 diabetic patients. Treating obesity may enhance hypoglycemic treatment and, thus, may contribute to a reduction in long-term microvascular and macrovascular
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